Prepared aconite tuber

Other Names

AconiteAconite rootAconiti Lateralis Radix PraeparataAconitum bodinieriAconitum carmichaelii DebeauxAconitum carmichaelii Debx.Aconitum chinenseAconitum fischeriAconitum fortuneiAconitum lushanenseAconitum takahashiiAconitum wilsoniiAutumn monkshoodAutumn-flowering monkshoodAzure monkshoodBai Fu PianBaifupianBushiCao WuCaowuCarmichael's monkshoodChinese aconiteChinese wolfsbaneChuan WuChuanwuDan Fu PianDanfupianFu ZiFuziHei Shun PianHeishunpianHelmet flowerKyeong-Po BujaMonkshoodMonkshood rootPao Fu PianPaofupianPaofuziPrepared aconite rootProcessed aconite rootProcessed aconite tuberRadix Aconiti Lateralis PraeparataRadix Aconiti Lateralis PreparataRadix Aconiti PraeparataTian XiongTianxiongTorikabutoWolfsbaneWu TouWutouYan Fu ZiYanfuziZhi Chuan WuZhichuanwu制川乌川乌烏頭草乌附子鳥兜

Synopsis

Prepared Aconite Tuber (Aconiti Lateralis Radix Praeparata / Fuzi)

1. Identity: Botanical Names, Natural Source, and Common Forms

Botanical and Pharmacopeial Names

The processed lateral root of Aconitum carmichaelii Debeaux (family Ranunculaceae) is an extensively used traditional Chinese medicine known as Fuzi in China, bushi in Japan, and Kyeong-Po Buja in Korea; it is also called Chinese aconite, monkshood, or Chinese wolfsbane in English-language sources. The pharmacopeial designation in Latin is Aconiti Lateralis Radix Praeparata. Additional scientific names of closely related species used medicinally include Aconitum kusnezoffii Rchb. and Aconitum napellus L.; common English vernacular names encompass aconite, wolfsbane, blue rocket, devil's helmet, friar's cap, and monkshood.

Botanical Source

In TCM, both the "daughter root" (Fu Zi) and the "mother root" (Chuan Wu Tou) of the same species (A. carmichaelii) are used medicinally. Fuzi is derived from the lateral roots of A. carmichaelii Debx. The Compendium of Materia Medica records that the plant is "first planted as aconite, like the head of a crow," and that the daughter root, attached to and born from the parent root, was named Fuzi. Shennong's Classic of Materia Medica (Shennong Bencao Jing) was the first text to record the taste and efficacy of Fuzi, classifying it as "lower grade," meaning highly toxic — indicating it has been used in medicine for over a thousand years.

Common Processed Forms

The recognized processed forms include Yanfuzi (salt-processed), Heishunpian (black sliced aconite), Baifupian (white sliced aconite), and Paofuzi (processed/boiled aconite), as specified by the Chinese Pharmacopoeia Commission. The preparations differ in their methods of preparation:

Yanfuzi: soaked with salts (MgCl₂ or NaCl) and dried in the sun; the surface is usually covered with salts.
Heishunpian: soaked with salts and boiled in water, resulting in the formation of a transparent mass; the mass is sliced, brown sugar with oil is added giving the slices a brown color; slices are then steamed, roasted, and dried.
Baifupian: soaked with salts and boiled in water, leading to the formation of a transparent product; this product is sliced, steamed, and smoked with sulfur, rendering the slices white in color.
Danfupian: Yanfuzi is cleaned from salt by soaking in water; the product is sliced, boiled with licorice and black beans, and finally dried in the sun.
Paofupian: Yanfuzi salt is removed by soaking in water; the preparation is then sliced, soaked with ginger juice, roasted, and fried.

Using the traditional Chinese processing system known as Paozhi, the three main pharmacopeial forms of processed aconite — Yanfuzi, Heishunpian, and Baifupian — can be obtained. Some new processing techniques have been developed in China, such as pressure-steaming.

2. Traditional and Historical Use

Traditional Chinese Medicine

In traditional Chinese medicine (TCM), species such as Aconitum carmichaelii and Aconitum kuznezoffii have been employed for over 2,000 years, with roots and tubers processed through methods like boiling or steaming to mitigate toxicity before use in treating conditions including syncope, collapse, severe pain, arthritis, and inflammation. In TCM, processed aconite is called the "King of 100 Herbs" and is famous for tonifying Yang.

Fuzi is prescribed by TCM doctors to manage life-threatening situations such as cold extremities and weak pulse, and this practice started at least 2,000 years ago. TCM Fuzi decoction served as a life-saving prescription at a time when no Western medicine was available to treat diseases. It has been used to treat shock resulting from acute myocardial infarction, low blood pressure, coronary heart disease, and chronic heart failure.

In traditional Asian medicine, aconite root extracts are typically mixed with other ingredients, such as licorice or ginger. Shenfu decoction — containing Asian ginseng and aconite root — is a traditional medicine used historically for heart failure. Fuzi is first recorded as having a hot nature and pungent flavor in Shennong's Classic of Materia Medica, and has been used for centuries for therapeutic potential in heart failure, rheumatoid arthritis, gastroenteritis, depression, and other diseases.

Use in Ayurvedic and Tibetan Medicine

The Aconitum family has a long history of effective use in Traditional Chinese Medicine (TCM), Tibetan Medicine, and Ayurvedic Medicine. In all these systems, "black" aconite (associated with A. carmichaelii in TCM, A. napellus in Europe, and A. ferox in Ayurvedic medicine) required processing to remove the numbing and toxic properties. The Ayurvedic processing method is called Shodhana. Comparative studies demonstrate that Ayurvedic Shodhana and Chinese TCM processing methods both effectively convert diester diterpenoid alkaloids into monoester diterpenoid alkaloids; among the studied methods, processing with water was found more efficient than Shodhana with cow milk or cow urine.

Western Historical Use

Historically, aconite was most commonly used in Western cultures as a tincture. The Austrian Pharmacopeia (Pharmacopoeia Austriaca) was the official pharmacopoeia of the Slovenian territory in the nineteenth century. A monograph entitled Aconitum and a recipe for the extract of aconite herb was included in the first five editions of this pharmacopoeia (1812, 1814, 1820, 1834, and 1855). Based on accounts in Chinese and Western sources, aconite root extracts were a principal ingredient in arrow poisons used for at least 2,500 years in various parts of China.

Extracts of Aconitum species have been used orally in traditional medicine to reduce fever associated with colds, pneumonia, laryngitis, croup, and asthma; and for analgesic, anti-inflammatory, hypotensive, diuretic, diaphoretic, cardiac depressant, and sedative effects.

3. Key Constituents and Active Compounds

Alkaloid Classes

The main components of A. carmichaelii are C₁₉-diterpene alkaloids (C₁₉-DAs), among which diester-type aconitine is the most toxic and also the main active ingredient, while monoester diterpene alkaloids (MDAs) and aminol diterpene alkaloids (ADAs) are greatly reduced in toxicity due to the loss of ester bonds. The plant also contains abundant C₂₀-diterpene alkaloids (C₂₀-DAs).

The current quality markers (Q-markers) for controlling Fuzi's efficacy and toxicity are three monoester-diterpenoid alkaloids — benzoylaconine (BAC), benzoylhypaconine, and benzoylmesaconine (BMA) — and three diester-diterpenoid alkaloids — aconitine (AC), hypaconitine, and mesaconitine (MA).

In addition to these known toxic alkaloids (aconitine, mesaconitine, hypaconitine) and bioactive alkaloids (benzoylaconine, benzoylmesaconine, benzoylhypaconine), three more rarely found alkaloids have been reported in Fuzi: yunaconitine, 8-deacetyl-yunaconitine, and crassicauline A, which were reported in recent years to pose potential risk to patients.

About 26 lipo-alkaloids have been identified from the roots of A. carmichaelii. Studies have shown that the main chemical components of Fuzi are alkaloids, which can be divided into diester-type alkaloids, monoester-type alkaloids, and other types of alkaloids.

Non-Alkaloid Constituents

Constituents such as alkaloids, polysaccharides, flavonoids, fatty acids, ceramides, and trace elements are the material basis for Fuzi to exert a variety of functions. Fuzi polysaccharides have been identified as capable of exerting immunomodulatory and hypoglycemic effects.

Chemistry of Processing: How Toxic Alkaloids Are Transformed

During processing, the diester-type alkaloids (extremely toxic) are hydrolyzed into monoester-type alkaloids (mildly toxic) by deacetylation, and the monoester-type alkaloids can be further hydrolyzed into benzoylmesaconine by debenzoylation. Water soaking is the most commonly used processing strategy for reducing the toxicity of these herbal medicines.

Traditional detoxification techniques primarily hydrolyse toxic diester diterpenoid alkaloids (DDAs) into less toxic MDAs or ADAs through removal of ester groups at the C8 and C14 positions, resulting in safer derivatives while retaining part of the desired pharmacological activity. For example, processing converts aconitine into less toxic derivatives such as benzoylaconine and aconine; however, these products should be interpreted as lower-risk rather than risk-free.

The non-ester type alkaloid resulting from hydrolysis has a toxicity of 1/150–1/200 compared with the original alkaloid; if one ester portion is cut away to become alkamine, the toxicity is lowered to 1/2,000.

4. Mechanisms of Action

Ion Channel Actions (Toxic and Therapeutic)

The cardiotoxicity and neurotoxicity of aconitine and related alkaloids are due to their actions on the voltage-sensitive sodium channels of the cell membranes of excitable tissues, including the myocardium, nerves, and muscles. Aconitine reaches the α-subunit of Na⁺-channel receptors through the lipophilic part of the membrane and binds the neurotoxin binding site 2, causing cell depolarization and permanent activation of channels themselves.

The major bioactive components of Fuzi for cardiotonic effects are total alkaloids, polysaccharides, and water-soluble alkaloids, with specific mechanisms manifested in the inhibition of myocardial fibrosis, apoptosis, and autophagy, and improvement of mitochondrial energy metabolism, involving the RAAS system, PI3K/AKT, JAK/STAT, and AMPK/mTOR signaling pathways.

Diester-diterpenoid alkaloids in Fuzi can produce cardiotoxic effects by over-activating Na⁺ and Ca²⁺ ion channels, over-activating NLRP3/ASC/caspase-3 inflammatory pathway, and mitochondria-mediated apoptosis pathway.

The diester aconitine contained in this herb has cardiotoxicity and neurotoxicity, which is the main reason for its narrow therapeutic window and limited clinical application. However, more and more studies have shown that low doses of diester aconitine or its hydrolysates have a strong cardioprotective effect.

Anti-Inflammatory Mechanisms

The mechanism of action of aconite-containing preparations in cardiovascular contexts is mainly related to reducing inflammation through the NF-κB signaling pathway, oxidative stress by reducing free radical damage, dilating blood vessels by increasing nitric oxide (NO) content, decreasing fibrosis through the TGF-β/Smads signaling pathway, and reducing apoptosis by increasing the expression of apoptosis proteins.

Further studies in ACE2-knockdown cells and ACE2⁻/⁻ mice suggested that benzoylaconitine targeted ACE2 to suppress p38/ERK-mediated mitochondrial ROS and NF-κB pathway activation. Findings suggest that benzoylaconitine is a promising ACE2 agonist in regulating mitochondrial ROS release and inflammation activation to improve cardiac function in heart failure.

Analgesic Mechanisms

Alkaloids also exert their actions by interacting with Na⁺ channels, opioid receptors, and serotonin receptors. Aconitine modulates noradrenaline and acetylcholine release, favors lipid peroxidation and cell apoptosis, and has inhibitory effects on neuronal activity in rat hippocampal slices in vitro.

Cardiotonic Mechanisms

Pharmacological experiments have confirmed that Shenfu Injection (a combined aconite-ginseng preparation) can enhance myocardial contractility, increase cardiac output, and inhibit cardiomyocyte apoptosis caused by myocardial ischemia/reperfusion injury, among other cardiovascular effects.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Disease and Heart Failure

Fuzi has been widely used in TCM for the treatment of acute heart failure for 2,000 years. However, the clinical evidence of Fuzi in the treatment of chronic heart failure is limited, especially when used in combination with Western medications.

A population-based propensity score-matched cohort study aimed to evaluate the effectiveness of Fuzi on chronic heart failure. From 4,735 chronic heart failure patients who had used TCM herbal medicine, 1:1 propensity score matching selected target patients with (n = 921) and without (n = 921) Fuzi use; primary outcomes were all-cause mortality and composite cardiovascular outcomes.

Shenfu Injection (SFI), composed of ginseng and aconite, is a Chinese patent medicine developed from the classic Shenfu Decoction created more than 700 years ago; SFI has been widely used in China for over 30 years for treating cardiovascular diseases. Shenfu injection is a refined suspension mainly containing ginsenosides and aconitines; its primary effects include diuresis, reduction of myocardial oxygen consumption, alleviation of ischemia-reperfusion injury, and inhibition of inflammatory reactions. Evidence for Shenfu Injection in cardiovascular settings is substantially preclinical or based on retrospective and observational Chinese clinical datasets; high-quality randomized controlled trial evidence in Western populations is absent.

5.2 Pain and Rheumatoid Arthritis

Many scholars have confirmed that the modern pharmacological effects of Fuzi include cardiotonic, analgesic, anti-inflammatory, antitumor, and protection from ischemic myocardium. Fuzi is specifically used to treat cardiovascular diseases, rheumatoid arthritis, and other diseases in Korea, Japan, and India.

Fuzi is a popular TCM well known for both therapeutic and high-toxic activities; its toxic alkaloid ingredients — mainly aconitine, mesaconitine, and hypaconitine — are responsible for the high toxicity. In a collagen-induced arthritis (CIA) mouse model, significant IL-6 and TNF-α elevation was observed alongside reduced hepatic CYP3A4-homolog and P-gp expression; pharmacokinetic analysis revealed remarkable increases in aconitine, mesaconitine, and hypaconitine exposure following oral administration of Fuzi preparations in CIA mice compared with controls. This finding is from animal studies and has not been replicated in controlled human clinical trials.

Aconitum species are widely used in the clinical treatment of rheumatism, arthritis, bruise, fracture, pain, and other diseases in China and other Asian countries; however, due to their potential proarrhythmic effect, Aconitum and its related preparations are now restrictively used. Clinical evidence in this area remains largely observational and embedded in multi-herb formulas, and rigorous placebo-controlled human trials are lacking.

5.3 Anticancer Properties

In clinical practice Fuzi is often used to treat heart failure, rheumatoid arthritis, and different kinds of pain. Fuzi extract and its active ingredients exert considerable anticancer, anti-inflammatory, and analgesic effects. The main chemical substances include alkaloids, polysaccharides, flavonoids, fatty acids, and sterols; among them, alkaloids and polysaccharides are responsible for the anticancer efficacy.

The anticancer effects are largely attributed to inducing apoptosis and autophagy, inhibiting proliferation, migration and invasion, regulating body immunity, affecting energy metabolism, as well as reversing multidrug resistance. In the treatment of malignant tumors, Fuzi is believed to improve the prognosis of advanced primary liver cancer; after drug intervention in one report, the median survival time of patients was extended from 4.85 to 6.74 months. This is preliminary clinical data from a single study embedded within multi-herb TCM formulas; independent, well-controlled human trials are not currently available.

In recent years, some traditional herbal compounds containing Fuzi have achieved positive clinical results in tumor treatment, and the polysaccharide isolated from Fuzi has attracted much attention as a potential immunomodulator; however, its immunomodulatory mechanism remains to be further studied. Evidence in oncology for prepared aconite is predominantly preclinical (in vitro and animal models), and human data are not yet sufficient to draw firm conclusions.

5.4 Immunomodulation and Hypoglycemia

Fuzi polysaccharides can exert immunomodulatory and hypoglycemic effects. The polysaccharide isolated from Fuzi has attracted attention as a potential immunomodulator. These findings are primarily based on animal and cell-based experiments; human clinical data are not available.

5.5 Depression and Neurological Areas

Fuzi has been used for centuries and offers therapeutic potential for heart failure, rheumatoid arthritis, gastroenteritis, depression, and other diseases. The evidence base for depression is preliminary and confined to preclinical settings; no clinical trials in humans for this indication have been identified in peer-reviewed sources.

Summary of Evidence Strength

With correct processing based on traditional experience and new techniques, prepared aconite can be used safely, and it has a wide range of therapeutic uses; however, the full range of activities of the different constituents is still being elucidated. Across all areas of use, the existing human clinical evidence is largely observational, retrospective, or embedded in multi-herb formulas in which prepared aconite is one of several components; independent, placebo-controlled randomized trials are sparse, and the overall quality of evidence is low to moderate by contemporary standards.

6. Body Systems and Health Areas Associated with Prepared Aconite Tuber

Cardiovascular system: Fuzi is used for cardiovascular, rheumatologic, gastrointestinal, and pain-related conditions; despite long-standing use, application is constrained by a narrow therapeutic index, variable processing practices, and recurrent reports of poisoning.
Musculoskeletal / rheumatological system: The tubers and roots of Aconitum have been widely used as analgesic agents for the treatment of coronary heart disease, chronic heart failure, rheumatoid arthritis, and neuropathic pain since ancient times.
Nervous system: Aconite extracts have been used traditionally for analgesic, diaphoretic, cardiac depressant, and sedative effects, as well as to reduce fever associated with respiratory conditions.
Immune system / oncology: Research has demonstrated that Fuzi exhibits a range of beneficial effects, including cardiomyocyte protection, antiarrhythmic, anti-inflammatory, and analgesic properties. Among its constituents, benzoylaconine demonstrates notable pharmacological properties including antitumor, anti-inflammatory, and cardiovascular protective effects.
Endocrine system: Fuzi is also used to treat some endocrine disorders like irregular menstruation and dysmenorrhea.
Gastrointestinal system: Fuzi is used for gastrointestinal conditions including diarrhoea and gastroenteritis.

7. Dosage Forms and Dosages Reported in Sources

The Chinese Pharmacopoeia 2020 explicitly specifies the clinical use of Fuzi at a dose of 3–15 g per day, and it needs to be decocted first or for a long time during decoction. The Chinese Pharmacopoeia explicitly stipulates that aconite must be decocted before use, with a dosage range of 3–15 g.

The Chinese Pharmacopoeia specifies 1.5 to 3 g per dose for processed Zhi Chuan Wu (the prepared parent root), always in decoction form; it must be decocted first for at least 30 to 60 minutes before adding other herbs, to further hydrolyse residual toxic alkaloids through prolonged heating.

Clinical and analytical data demonstrate that longer boiling times (10–120 min) progressively hydrolyse DDAs into MDAs and ADAs. Baifupian boiled for two hours exhibited no measurable toxicity in mice, with aconitine undetectable by HPLC, whereas shorter boiling times (30–60 min) retained residual toxicity. Total alkaloid content remains relatively stable, indicating transformation rather than elimination of compounds. Therapeutic efficacy is preserved across boiling durations.

Shenfu Injection, a standardized injectable containing ginsenosides and aconite alkaloids, contains ginsenosides at 676–742 µg/mL and aconite alkaloids at 3–7 µg/mL.

Prepared aconite is most commonly administered as part of a decocted formula in TCM practice. Various adjuvants are commonly used to balance therapeutic efficacy with safety; some of the most commonly used adjuvants to neutralize toxic alkaloids include saltwater, ginger juice, rice water, vinegar, wine, and brine.

8. Safety Considerations and Interactions

Inherent Toxicity and Therapeutic Window

Fuzi has a narrow margin of safety since its pharmacological constituents, aconitum alkaloids, have potential cardiotoxicity and neurotoxicity. Aconitine, a highly toxic component of Fuzi, can cause poisoning in adults at 0.2 mg orally and can be fatal at 2–4 mg, which makes Fuzi contraindicated in standard clinical utilization without appropriate preparation.

Fresh aconite is extremely toxic, and safe dosing is dependent on processing. Many species are used medicinally in China only after processing. Processing may reduce alkaloid content and/or alter alkaloid composition, thus reducing potency; however, poisoning may still occur after consumption of processed aconite root.

Clinical Symptoms of Toxicity

As little as 2 mg of pure aconitine or 1 g of aconite plant may cause death. Aconitine's toxicity is characterized by a burning sensation of the lips, tongue, mouth, and throat almost immediately following ingestion, which may be followed by numbness of the oral cavity and throat and difficulty in speech. Salivation, nausea, vomiting, dizziness, syncope, palpitation, and diarrhea may occur. There may be visual blurring or yellow-green color vision distortion, weakness, and incoordination. Toxicity mainly affects the cardiovascular system and the neuromuscular system.

Cardiovascular features include hypotension, chest pain, palpitations, bradycardia, sinus tachycardia, ventricular ectopics, ventricular tachycardia, and ventricular fibrillation. Aconitine may induce fatal ventricular arrhythmias and severe central nervous system disturbances when improperly used.

Factors Altering Toxicity

Alcohol enhances the absorption and toxicity of aconitine, lowering the threshold for a lethal dose. Toxicokinetic differences of A. carmichaelii after administration may be closely related to cytochrome P450 enzyme polymorphism and processing parameters. CYP3A4 is responsible for the primary metabolism of aconitine.

In a collagen-induced arthritis mouse model, significant IL-6 and TNF-α elevation was accompanied by reduced hepatic CYP3A4-homolog and P-gp expression. Pharmacokinetic analysis revealed increases in aconitine, mesaconitine, and hypaconitine exposure following oral administration of Fuzi preparations in disease-state mice. Accumulation of these alkaloids in the heart, intestine, liver, and kidneys was significantly elevated in arthritis mice, and cardiotoxic markers were strongly correlated with alkaloid exposure. RA-induced cytokine dysregulation thus potentiates Fuzi's cardiotoxicity through CYP3A4/P-gp suppression-mediated pharmacokinetic alterations.

Alcohol may increase the absorption rate of aconitine alkaloids and heighten toxicity risk. Grapefruit and grapefruit juice, which inhibit CYP3A4 metabolism, may increase alkaloid blood levels.

Herb–Drug Interactions and Compatibility

Herbal-herbal combinations to reduce toxicity are an area of active research. For example, the alkaloid in Fangji (Stephania tetrandra) could inhibit the movement of calcium ions crossing the L-type calcium channel, which in turn lowers the toxic arrhythmic effect of aconite alkaloids.

Aconite has certain toxicity, and the use of red ginseng in combination can achieve the effect of potentiation and detoxification. Ginsenosides can promote the metabolism of the toxic component aconitine, prolong the elimination half-life of active ingredients such as hypaconitine, benzoylmesaconine, and songorine, and significantly increase the in vivo exposure of active ingredients.

Management of Poisoning

Immediate treatment typically includes the administration of intravenous fluids, antiarrhythmic agents, and other supportive measures to manage cardiovascular instability. Magnesium sulfate and amiodarone are commonly used to address arrhythmias associated with aconite toxicity. Management is supportive; the early use of cardiopulmonary bypass is recommended if ventricular arrhythmias and cardiogenic shock are refractory to first-line treatment. Aconite toxicity is attributed to aconitine, which disrupts cellular function by binding to voltage-gated sodium channels. Management focuses on supportive care and symptomatic treatment, given the absence of a specific antidote.

Regulatory and Quality Control Notes

Processed forms such as Baifupian, Heishunpian, and Yanfuzi exhibit markedly reduced toxicity compared with crude Fuzi, but their safety still depends on validated processing, dosage control, and analytical confirmation of residual toxic alkaloids. Although traditional processing methods can achieve the desired detoxification effect, there are some obvious drawbacks, including significant loss of alkaloids and poor quality consistency. HPLC is an appropriate means of quality control for aconite preparations.

Severe or even fatal aconite poisoning can occur after consumption of herbal soups and foods prepared from aconite roots. Even prolonged boiling may not be protective if raw preparations and large quantities of aconite roots are used.

References

Health Conditions

Health conditions that Prepared aconite tuber may help support.

No conditions available.

Body Systems

Body systems that Prepared aconite tuber may help support.

No body systems available.